FDA Panel Schedules Date to Review Exact Sciences' Cologuard Application | GenomeWeb

NEW YORK (GenomeWeb News) – Exact Sciences said after the close of the market Tuesday that the US Food and Drug Administration's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is tentatively scheduled to review the firm's premarket approval application for its Cologuard DNA-based, non-invasive colorectal cancer screening test on March 26, 2014.

The date is subject to confirmation by the FDA in the Federal Register.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.